A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder

American Journal on Addictions

Volumn 19, Issue 6, 2010, Pages 481-489

  McRae Clark, Aimee L ^a   Carter, Rickey E ^b   Killeen, Therese K ^a   Carpenter, Matthew J ^a   White, Kathleen G ^a   Brady, Kathleen T ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CANNABIS; PLACEBO;

ADULT; ALLERGY; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; CANNABIS ADDICTION; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HEADACHE; HOT FLUSH; HUMAN; INSOMNIA; IRRITABILITY; MALE; MARIJUANA CRAVING QUESTIONNAIRE; MOTIVATION; MUSCULOSKELETAL DISEASE; POLYURIA; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY TRACT DISEASE; RISK FACTOR; SAMPLE SIZE; SCORING SYSTEM; SELF CONCEPT; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUSITIS; SYMPTOM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WENDER REIMHERR ADULT ATTENTION DEFICIT DISORDER SCALE; XEROSTOMIA;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DIAGNOSIS, DUAL (PSYCHIATRY); DOUBLE-BLIND METHOD; DRUG-SEEKING BEHAVIOR; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; PLACEBOS; PROPYLAMINES; SELF REPORT;

EID: 78349292268     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2010.00076.x     Document Type: Article

References (48)

1. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: National Findings (NSDUH Series H-34, DHHS Publication No. SMA 08-4343). Rockville, MD; 2008.
2. Anthony JC, Warner LA, Kessler RC,. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exper Clin Psychopharmacol. 1994; 2: 244-268.
3. Mannuzza S, Klein RG, Bessler A, et al,. Adult outcome of hyperactive boys: Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993; 50: 565-576.
4. Biederman J, Wilens T, Mick E, et al,. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): Effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995; 152: 1652-1658.
5. Murphy K, Barkley RA,. Attention deficit hyperactivity disorder adults: Comorbidities and adaptive impairments. Compr Psychiatry. 1996; 37: 393-401. (Pubitemid 26383062)
6. Barkley RA,. ADHD in adults. In: Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, 3rd edn. New York, NY: Guilford Press; 2006: 248-296.
7. Kessler RC, Adler LA, Barkley R, et al,. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey replication. Am J Psychiatry. 2006; 163: 716-723.
8. Biederman J, Faraone SV, Spencer T, et al,. Patterns of psychiatric co-morbidity, cognition and psychosocial functioning in adults with attention deficit disorder. Am J Psychiatry. 1993; 150: 1792-1798.
9. Sullivan MA, Rudnik-Levin F,. Attention deficit/hyperactivity disorder and substance abuse. Diagnostic and therapeutic considerations. Ann N Y Acad Sci. 2001; 931: 251-270.
10. Biederman J, Wilens TE, Mick E, et al,. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry. 1998; 44: 269-273.
11. Wilens TE, Biederman J, Mick E,. Does ADHD affect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am J Addict. 1998; 7: 156-163.
12. Schubiner H,. Substance abuse in patients with attention-deficit hyperactivity disorder: Therapeutic implications. CNS Drugs. 2005; 19: 643-655.
13. Biederman J,. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: Findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry. 2003; 64 (Suppl 11): 3-8.
14. Faraone SV, Wilens TE,. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and potential for stimulant misuse, abuse, and diversion. J Clin Psychiatry. 2007; 68 (Suppl 11): 15-22.
15. Wilens TE, Adamson J, Monuteaux MC, et al,. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med. 2008; 162: 916-921.
16. Schubiner H, Saules KK, Arfken CL, et al,. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol. 2002; 10: 286-294.
17. Levin FR, Evans SE, Brooks DJ, et al,. Treatment of cocaine dependent treatment seekers with adult ADHD: Double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 2007; 87: 20-29.
18. Spencer T, Biederman J, Wilens T, et al,. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1998; 155: 693-695. (Pubitemid 28225414)
19. Stahl SM,. Selective NRIs are smart drugs: Exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry. 2003; 64: 110-111.
20. Wilens TE, Adler LA, Weiss MD, et al,. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008; 96: 145-154.
21. Applegate B, Lahey BB, Hart EL, et al,. Validity of the age-of-onset criterion for ADHD: A report from the DSM-IV field trials. J Am Acad Child Adolesc Psychiatry. 1997; 36: 1211-1221.
22. Faraone SV, Biederman J, Doyle A, et al,. Neuropsychological studies of late onset and subthreshold diagnoses of adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006; 60: 1081-1087. (Pubitemid 44754858)
23. Faraone SV, Biederman J, Spencer T, et al,. Diagnosing adult attention deficit hyperactivity disorder: Are late onset and subthreshold diagnoses valid? Am J Psychiatry. 2006; 163: 1720-1729.
24. First MB, Spitzer RL, Gibbon M, et al,. Structured Clinical Interview for Axis I DSM-IV Disorders, Patient edn (SCID-I/P, Version 2.0). New York, NY: Biometrics Research Department; 1994.
25. Folstein MF, Folstein SE, McHugh PR,. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-198.
26. Conners CK, Erhardt D, Sparrow E,. Conners' Adult ADHD Rating Scales (CAARS). North Tonawanda, NY: Multi-Health Systems; 1999.
27. Sobell MB, Sobell LC,. Behavioral Treatment of Alcohol Problems. New York, NY: Plenum Press; 1978.
28. Heishman SJ, Singleton EG, Ligouri A,. Marijuana Craving Questionnaire: Development and initial validation of a self-report instrument. Addiction. 2001; 96: 1023-1034.
29. Guy W,. ECDEU Assessment Manual for Psychopharmacology, Revised 1976. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch; 1976: 217-222, 313-331.
30. Hamilton M,. The assessment of anxiety states by rating. Br J Psychiatry. 1959; 32: 50-55.
31. Hamilton M,. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 56-61.
32. Wender PH, Reimherr FW, Wood D, et al,. A controlled study of methylphenidate in the treatment of attention-deficit disorder in adults. Am J Psychiatry. 1985; 142: 547-552.
33. Miller WR, Benefield GS, Tonigan JS,. Enhancing motivation for change in problem drinking: A controlled comparison of two therapist styles. J Consult Clin Psychol. 1993; 61: 455-461.
34. Stephens RS, Roffman RA, Curtin L,. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol. 2000; 68: 898-908.
35. McRae AL, Brady KT, Carter RE,. Buspirone for treatment of marijuana dependence: A pilot study. Am J Addict. 2006; 15: 404.
36. Meinert CL,. Clinical Trials Design, Conduct, and Analysis. New York: Oxford University Press; 1986.
37. Mendenhall W, Sinich T,. A Second Course in Statistics: Regression Analysis, 5th edn. Upper Saddle River, NJ: Prentice Hall, Inc.; 1996.
38. Hedden SL, Woolson RF, Carter RE, et al,. The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse clinical trials. J Substance Abuse Treat. 2009; 37: 54-63.
39. McCullagh P, Nelder JA,. Generalized Linear Models. London: Chapman and Hall; 1989.
40. Liang KY, Zeger SL,. Longitudinal data analysis using generalized linear models. Biometrika. 1986; 73: 13-22.
41. Kraemer HC, Mintz J, Noda A, et al,. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry. 2006; 63: 484-489.
42. Michelson D, Adler L, Spencer T, et al,. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry. 2003; 53: 112-120.
43. Solowij N, Mitchie PT, Fox AM,. Differential impairments of selective attention due to frequency and duration of cannabis use. Biol Psychiatry. 1995; 37: 731-739.
44. Heishman SJ, Arasteh K, Stitzer ML,. Comparative effects of alcohol and marijuana on mood, memory and performance. Pharmacol Biochem Behav. 1996; 58: 93-101.
45. Pope HG, Yurgelun-Todd D,. The residual effects of heavy marijuana use in college students. JAMA. 1996; 275: 521-527.
46. Pope HG, Gruber AJ, Hudson JI, et al,. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. 2001; 58: 909-915.
47. Tirado CF, Goldman M, Lynch K, et al,. Atomoxetine for treatment of marijuana dependence: A report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. Drug Alcohol Depend. 2008; 94: 254-257.
48. Levin FR, Mariani JJ, Secora A, et al,. Atomoxetine treatment for cocaine abuse and adult attention deficit/hyperactivity disorder (ADHD): A preliminary open trial. J Dual Diagn. 2009; 5: 41-56.